Skip to main content Accessibility help
×
×
Home

Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples

  • Chiara Fabbri (a1), Siegfried Kasper (a2), Alexander Kautzky (a3), Lucie Bartova (a3), Markus Dold (a4), Joseph Zohar (a5), Daniel Souery (a6), Stuart Montgomery (a7), Diego Albani (a8), Ilaria Raimondi (a9), Dimitris Dikeos (a10), Dan Rujescu (a11), Rudolf Uher (a12), Cathryn M. Lewis (a13), Julien Mendlewicz (a14) and Alessandro Serretti (a15)...

Abstract

Background

Treatment-resistant depression (TRD) is the most problematic outcome of depression in terms of functional impairment, suicidal thoughts and decline in physical health.

Aims

To investigate the genetic predictors of TRD using a genome-wide approach to contribute to the development of precision medicine.

Method

A sample recruited by the European Group for the Study of Resistant Depression (GSRD) including 1148 patients with major depressive disorder (MDD) was characterised for the occurrence of TRD (lack of response to at least two adequate antidepressant treatments) and genotyped using the Infinium PsychArray. Three clinically relevant patient groups were considered: TRD, responders and non-responders to the first antidepressant trial, thus outcomes were based on comparisons of these groups. Genetic analyses were performed at the variant, gene and gene-set (i.e. functionally related genes) level. Additive regression models of the outcomes and relevant covariates were used in the GSRD participants and in a fixed-effect meta-analysis performed between GSRD, STAR*D (n = 1316) and GENDEP (n = 761) participants.

Results

No individual polymorphism or gene was associated with TRD, although some suggestive signals showed enrichment in cytoskeleton regulation, transcription modulation and calcium signalling. Two gene sets (GO:0043949 and GO:0000183) were associated with TRD versus response and TRD versus response and non-response to the first treatment in the GSRD participants and in the meta-analysis, respectively (corrected P = 0.030 and P = 0.027).

Conclusions

The identified gene sets are involved in cyclic adenosine monophosphate mediated signal and chromatin silencing, two processes previously implicated in antidepressant action. They represent possible biomarkers to implement personalised antidepressant treatments and targets for new antidepressants.

Declaration of interest

D.S. has received grant/research support from GlaxoSmithKline and Lundbeck; has served as a consultant or on advisory boards for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen and Lundbeck. S.M. has been a consultant or served on advisory boards for: AstraZeneca, Bristol-Myers Squibb, Forest, Johnson & Johnson, Leo, Lundbeck, Medelink, Neurim, Pierre Fabre, Richter. S.K. has received grant/research support from Eli Lilly, Lundbeck, Bristol-Myers Squibb, GlaxoSmithKline, Organon, Sepracor and Servier; has served as a consultant or on advisory boards for AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, Lundbeck, Pfizer, Organon, Schwabe, Sepracor, Servier, Janssen and Novartis; and has served on speakers' bureaus for AstraZeneca, Eli Lily, Lundbeck, Schwabe, Sepracor, Servier, Pierre Fabre, Janssen and Neuraxpharm. J.Z. has received grant/research support from Lundbeck, Servier, Brainsway and Pfizer, has served as a consultant or on advisory boards for Servier, Pfizer, Abbott, Lilly, Actelion, AstraZeneca and Roche and has served on speakers' bureaus for Lundbeck, Roch, Lilly, Servier, Pfizer and Abbott. J.M. is a member of the Board of the Lundbeck International Neuroscience Foundation and of Advisory Board of Servier. A.S. is or has been consultant/speaker for: Abbott, AbbVie, Angelini, Astra Zeneca, Clinical Data, Boehringer, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Innovapharma, Italfarmaco, Janssen, Lundbeck, Naurex, Pfizer, Polifarma, Sanofi and Servier. C.M.L. receives research support from RGA UK Services Limited.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples
      Available formats
      ×

Copyright

Corresponding author

Correspondence: Alessandro Serretti, MD, PhD, Department of Biomedical and NeuroMotor Sciences, University of Bologna, Viale Carlo Pepoli 5, 40123 Bologna, Italy. Email: alessandro.serretti@unibo.it

References

Hide All
1GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388: 1545–602.
2Souery, D, Serretti, A, Calati, R, Oswald, P, Massat, I, Konstantinidis, A, et al. Switching antidepressant class does not improve response or remission in treatment-resistant depression. J Clin Psychopharmacol 2011; 31: 512–6.
3Tansey, KE, Guipponi, M, Hu, X, Domenici, E, Lewis, G, Malafosse, A, et al. Contribution of common genetic variants to antidepressant response. Biol Psychiatry 2013; 73: 679–82.
4Fabbri, C, Corponi, F, Souery, D, Kasper, S, Montgomery, S, Zohar, J, et al. The genetics of treatment-resistant depression: a critical review and future perspectives. Int J Neuropsychopharmacol 2018; April 21 (Epub ahead of print).
5American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn, revised) (DSM-IV-TR). APA, 2000.
6Sheehan, DV, Lecrubier, Y, Sheehan, KH, Amorim, P, Janavs, J, Weiller, E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59: 2233
7Montgomery, SA, Åsberg, M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382–9.
8Dold, M, Bartova, L, Mendlewicz, J, Souery, D, Serretti, A, Porcelli, S, et al. Clinical correlates of augmentation/combination treatment strategies in major depressive disorder. Acta Psychiatr Scand 2018; 137: 401–12.
9American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder (4th edn) (DSM-IV). APA, 1994.
10Trivedi, MH, Rush, AJ, Ibrahim, HM, Carmody, TJ, Biggs, MM, Suppes, T, et al. The inventory of depressive symptomatology, clinician rating (IDS-C) and self-report (IDS-SR), and the quick inventory of depressive symptomatology, clinician rating (QIDS-C) and self-report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med 2004; 34: 7382.
11Rush, AJ, Fava, M, Wisniewski, SR, Lavori, PW, Trivedi, MH, Sackeim, HA, et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 2004; 25: 119–42.
12World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. WHO, 1992.
13Hamilton, M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 5662
14 Iniesta, R, Malki, K, Maier, W, Rietschel, M, Mors, O, Hauser, J, et al. Combining clinical variables to optimize prediction of antidepressant treatment outcomes. J Psychiatr Res 2016; 78: 94102.
15Souery, D, Oswald, P, Massat, I, Bailer, U, Bollen, J, Demyttenaere, K, et al. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry 2007; 68: 1062–70.
16Fabbri, C, Tansey, KE, Perlis, RH, Hauser, J, Henigsberg, N, Maier, W, et al. New insights into the pharmacogenomics of antidepressant response from the GENDEP and STAR*D studies: rare variant analysis and high-density imputation. Pharmacogenomics J 2017; 18: 413–21.
17Patterson, N, Price, AL, Reich, D. Population structure and eigenanalysis. PLoS Genet 2006; 2: e190.
18Li, Y, Willer, CJ, Ding, J, Scheet, P, Abecasis, GR. MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genet Epidemiol 2010; 34: 816–34.
19Dudbridge, F, Gusnanto, A. Estimation of significance thresholds for genomewide association scans. Genet Epidemiol 2008; 32: 227–34.
20Watanabe, K, Taskesen, E, van Bochoven, A, Posthuma, D. Functional mapping and annotation of genetic associations with FUMA. Nat Commun 2017; 8: 1826.
21de Leeuw, CA, Mooij, JM, Heskes, T, Posthuma, D. MAGMA: generalized gene-set analysis of GWAS data. PLoS Comput Biol 2015; 11: e1004219.
22Ionita-Laza, I, Lee, S, Makarov, V, Buxbaum, JD, Lin, X. Sequence kernel association tests for the combined effect of rare and common variants. Am J Hum Genet 2013; 92: 841–53.
23Chen, JJ, Roberson, PK, Schell, MJ. The false discovery rate: a key concept in large-scale genetic studies. Cancer Control J Moffitt Cancer Cent 2010; 17: 5862.
24Anderson, GR, Galfin, T, Xu, W, Aoto, J, Malenka, RC, Südhof, TC. Candidate autism gene screen identifies critical role for cell-adhesion molecule CASPR2 in dendritic arborization and spine development. Proc Natl Acad Sci U S A 2012; 109: 18120–5.
25Xu, C, Mullersman, JE, Wang, L, Bin Su, B, Mao, C, Posada, Y, et al. Polymorphisms in seizure 6-like gene are associated with bipolar disorder I: evidence of gene × gender interaction. J Affect Disord 2013; 145: 95–9.
26Maccarrone, G, Ditzen, C, Yassouridis, A, Rewerts, C, Uhr, M, Uhlen, M, et al. Psychiatric patient stratification using biosignatures based on cerebrospinal fluid protein expression clusters. J Psychiatr Res 2013; 47: 1572–80.
27Cross-Disorder Group of the Psychiatric Genomics Consortium. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet 2013; 381: 1371–9.
28Antypa, N, Drago, A, Serretti, A. Genomewide interaction and enrichment analysis on antidepressant response. Psychol Med 2014; 44: 753–65.
29Cai, S, Huang, S, Hao, W. New hypothesis and treatment targets of depression: an integrated view of key findings. Neurosci Bull 2015; 31: 6174.
30Tardito, D, Perez, J, Tiraboschi, E, Musazzi, L, Racagni, G, Popoli, M. Signaling pathways regulating gene expression, neuroplasticity, and neurotrophic mechanisms in the action of antidepressants: a critical overview. Pharmacol Rev 2006; 58: 115–34.
31Duman, RS, Malberg, J, Nakagawa, S, D'Sa, C. Neuronal plasticity and survival in mood disorders. Biol Psychiatry 2000; 48: 732–9.
32Hufgard, JR, Williams, MT, Skelton, MR, Grubisha, O, Ferreira, FM, Sanger, H, et al. Phosphodiesterase-1b (Pde1b) knockout mice are resistant to forced swim and tail suspension induced immobility and show upregulation of Pde10a. Psychopharmacology (Berl) 2017; 234: 1803–13.
33Jurek, B, Slattery, DA, Hiraoka, Y, Liu, Y, Nishimori, K, Aguilera, G, et al. Oxytocin regulates stress-induced Crf gene transcription through CREB-regulated transcription coactivator 3. J Neurosci 2015; 35: 12248–60.
34Tsankova, NM, Berton, O, Renthal, W, Kumar, A, Neve, RL, Nestler, EJ. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 2006; 9: 519–25.
35Lin, H, Geng, X, Dang, W, Wu, B, Dai, Z, Li, Y, et al. Molecular mechanisms associated with the antidepressant effects of the class I histone deacetylase inhibitor MS-275 in the rat ventrolateral orbital cortex. Brain Res 2012; 1447: 119–25.
36Erburu, M, Muñoz-Cobo, I, Diaz-Perdigon, T, Mellini, P, Suzuki, T, Puerta, E, et al. SIRT2 inhibition modulate glutamate and serotonin systems in the prefrontal cortex and induces antidepressant-like action. Neuropharmacology 2017; 117: 195208.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The British Journal of Psychiatry
  • ISSN: 0007-1250
  • EISSN: 1472-1465
  • URL: /core/journals/the-british-journal-of-psychiatry
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords

Type Description Title
UNKNOWN
Supplementary materials

Fabbri et al. supplementary material
Fabbri et al. supplementary material 1

 Unknown (5.2 MB)
5.2 MB

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples

  • Chiara Fabbri (a1), Siegfried Kasper (a2), Alexander Kautzky (a3), Lucie Bartova (a3), Markus Dold (a4), Joseph Zohar (a5), Daniel Souery (a6), Stuart Montgomery (a7), Diego Albani (a8), Ilaria Raimondi (a9), Dimitris Dikeos (a10), Dan Rujescu (a11), Rudolf Uher (a12), Cathryn M. Lewis (a13), Julien Mendlewicz (a14) and Alessandro Serretti (a15)...
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *